306 related articles for article (PubMed ID: 32721044)
1. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
[TBL] [Abstract][Full Text] [Related]
2. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
[TBL] [Abstract][Full Text] [Related]
3. Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression.
Kim HY; Yoo YH
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012166
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK.
Oh YJ; Kim HY; Lee MH; Suh SH; Choi Y; Nam TG; Kwon WY; Lee SY; Yoo YH
Mol Pharmacol; 2018 Dec; 94(6):1401-1411. PubMed ID: 30366981
[TBL] [Abstract][Full Text] [Related]
5. Hepatic STAMP2 alleviates polychlorinated biphenyl-induced steatosis and hepatic iron overload in NAFLD models.
Kim HY; Park CH; Park JB; Ko K; Lee MH; Chung J; Yoo YH
Environ Toxicol; 2022 Sep; 37(9):2223-2234. PubMed ID: 35616167
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
7. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
8. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway.
Wang ZQ; Zhang XH; Yu Y; Tipton RC; Raskin I; Ribnicky D; Johnson W; Cefalu WT
Metabolism; 2013 Sep; 62(9):1239-49. PubMed ID: 23702383
[TBL] [Abstract][Full Text] [Related]
9. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy.
Zhu S; Wu Y; Ye X; Ma L; Qi J; Yu D; Wei Y; Lin G; Ren G; Li D
Mol Cell Biochem; 2016 Sep; 420(1-2):107-19. PubMed ID: 27435856
[TBL] [Abstract][Full Text] [Related]
10. High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice.
Tsuchiya H; Ebata Y; Sakabe T; Hama S; Kogure K; Shiota G
Metabolism; 2013 Jan; 62(1):62-9. PubMed ID: 22854109
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
12. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
13. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
Chikamatsu M; Watanabe H; Shintani Y; Murata R; Miyahisa M; Nishinoiri A; Imafuku T; Takano M; Arimura N; Yamada K; Kamimura M; Mukai B; Satoh T; Maeda H; Maruyama T
J Control Release; 2023 Mar; 355():42-53. PubMed ID: 36690035
[TBL] [Abstract][Full Text] [Related]
14. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism].
Zhu SL; Zhang ZY; Ren GP; Ye XL; Ma L; Yu D; Han MM; Zhao JZ; Zhang TY; Li DS
Yao Xue Xue Bao; 2013 Dec; 48(12):1778-84. PubMed ID: 24689234
[TBL] [Abstract][Full Text] [Related]
16. Hepatic STAMP2 decreases hepatitis B virus X protein-associated metabolic deregulation.
Kim HY; Cho HK; Yoo SK; Cheong JH
Exp Mol Med; 2012 Oct; 44(10):622-32. PubMed ID: 23095254
[TBL] [Abstract][Full Text] [Related]
17. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload.
Zhu M; Chen H; Zhou S; Zheng L; Li X; Chu R; Chen W; Wang B; Wang M; Chai Z; Feng W
Nanotoxicology; 2021 Aug; 15(6):761-778. PubMed ID: 33961538
[TBL] [Abstract][Full Text] [Related]
18. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
19. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD.
Yang S; Cao SJ; Li CY; Zhang Q; Zhang BL; Qiu F; Kang N
J Ethnopharmacol; 2024 Oct; 332():118354. PubMed ID: 38762210
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
Su X; Kong Y; Peng D
Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
